IFNG and cancer: This is achieved through the binding of IFN-γ to IFN-γ receptor I (IFNGR1) on cancer cells, which subsequently activates the JAK/STAT signaling pathway to inhibit the transcriptional activity of downstream system Xc− [51, 52].